Europe — EMA
Yttriga (Yttrium-90)
Yttriga (Yttrium-90) is a radiopharmaceutical used for targeted therapy in medical treatments. This radioactive isotope delivers localized radiation for therape
Request sourcing
What is Yttrium-90?
Yttriga (Yttrium-90) is a radiopharmaceutical used for targeted therapy in medical treatments. This radioactive isotope delivers localized radiation for therapeutic purposes. Suitable for intravenous administration under professional supervision.
What is Yttrium-90 used for?
Yttrium-90, found in Yttriga, is primarily used in radiopharmaceutical therapies to treat certain cancers. It delivers targeted radiation to cancer cells while minimizing exposure to healthy tissue. This approach is often used in conditions requiring localized radiation therapy.
What are the side effects of Yttrium-90?
As a radioactive isotope, Yttrium-90 emits beta radiation to destroy targeted cells. Its effects are localized to the treatment area, reducing systemic impact. Patients may experience temporary effects related to the treatment site during administration.
What precautions apply to Yttrium-90?
Yttriga must be handled and administered by trained healthcare professionals only. Proper shielding and safety protocols are required due to its radioactive nature. Patients should follow all medical guidance regarding preparation and post-treatment care.
What does Yttrium-90 interact with?
Radiopharmaceuticals like Yttriga may interact with other medications or treatments affecting bone marrow or blood cell counts. Patients should disclose all current medications to their healthcare provider. Alcohol and certain supplements may also require caution during treatment.
